CytoDyn Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Consolidated Statement of Changes in Stockholders' (Deficit) Equity

Consolidated Statement of Changes in Stockholders' (Deficit) Equity - USD ($) shares in Thousands, $ in Thousands	Preferred Stock [Member]	Common Stock Registered Direct Offering [Member]	Common Stock Public Warrant Tender Offering [Member]	Common Stock Private Warrant Exchange [Member]	Common Stock Private Placement [Member]	Common Stock	Treasury Stock	Additional Paid-in Capital [Member] Registered Direct Offering [Member]	Additional Paid-in Capital [Member] Public Warrant Tender Offering [Member]	Additional Paid-in Capital [Member] Private Warrant Exchange [Member]	Additional Paid-in Capital [Member] Private Placement [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit	Registered Direct Offering [Member]	Public Warrant Tender Offering [Member]	Private Warrant Exchange [Member]	Private Placement [Member]	Total
Beginning balance at May. 31, 2018						$ 217						$ 159,765	$ (173,139)					$ (13,158)
Beginning balance, shares at May. 31, 2018	92					216,882	159
Acquisition of ProstaGene LLC, value						$ 19						11,539						11,558
Shares issued in acquisition						18,658
Issuance of stock payment shares, value						$ 8						(8)						0
Issuance of stock payment shares, shares						8,342
Issuance of stock for convertible note repayment, value						$ 4						1,451						1,455
Issuance of stock for convertible note, shares						3,756
Stock issued via offering, tender or placement, value		$ 24		$ 11	$ 47			$ 11,791		$ 2,955	$ 23,441	3,084		$ 11,815		$ 2,966	$ 23,488	3,084
Stock issued via offering, tender or placement, shares	3	23,630		11,312	46,975												47,000
Offering costs, stock and warrants								(1,130)		(267)	(2,697)			(1,130)		(267)	$ (2,697)
Issuance costs related to debt offering												261						261
Debt discount costs related to debt offering												3,059						3,059
Beneficial conversion feature on note payable and relative fair value associated with warrants												3,535						3,535
Inducement interest expense												196						196
Dividends accrued on preferred stock													(37)					(37)
Legal fees in connection with equity offerings												(243)						(243)
Stock-based compensation												3,388						3,388
Stock issued for services, value																		8
Net loss													(56,187)					(56,187)
Ending balance at May. 31, 2019						$ 330						220,120	(229,363)					(8,913)
Ending balance, shares at May. 31, 2019	95					329,555	159
Issuance of stock for convertible note repayment, value						$ 23						10,799						10,822
Issuance of stock for convertible note, shares						22,967
Stock issued via offering, tender or placement, value		$ 39	$ 45	$ 20				12,627	$ 11,855	6,001		13,409		12,666	$ 11,900	6,021		13,409
Stock issued via offering, tender or placement, shares	14	38,856	45,376	20,529
Offering costs, stock and warrants								$ (378)	(1,059)	(197)		(437)		$ (378)	(1,059)	(197)		(437)
SHARES PLACEHOLDER						8,232
Inducement interest expense									$ 2,713	5,191					$ 2,713	5,191
Dividends accrued on preferred stock													(945)					(945)
Legal fees in connection with equity offerings												(16)						(16)
Stock-based compensation												6,548						6,548
Note conversion and extension fees						$ 8						3,891						3,899
Warrant exercises, value						$ 42						20,458						20,500
Warrant exercises, shares						42,024
Relative fair market value associated with warrants exercised												11,949						11,949
Exercise of option to repurchase common stock, value												(8)						(8)
Stock issued for services, value						$ 3						(3)						3
Stock issued for services, shares						2,620
Stock issued for incentive compensation and tendered for income tax												154						154
Stock issued for incentive compensation and tendered for income tax , shares						380	127
Stock option exercises, value						$ 9						5,594						5,603
Stock option exercises, shares						8,723
Stock issued in legal settlement, value												22,500						22,500
Net loss													(124,403)					(124,403)
Ending balance at May. 31, 2020						$ 519						351,711	(354,711)					$ (2,481)
Ending balance, shares at May. 31, 2020	109					519,262	286
Issuance of stock payment shares, shares																		8,300
Issuance of stock for convertible note repayment, value						$ 24						77,679						$ 77,703
Issuance of stock for convertible note, shares						24,154
Stock issued via offering, tender or placement, value				$ 37	$ 1					17,519	$ 999					17,556	$ 1,000
Stock issued via offering, tender or placement, shares				37,054	667
Offering costs, stock and warrants										$ (495)						$ (495)
Inducement interest expense												11,366						11,366
Dividends accrued on preferred stock													(1,909)					(1,909)
Stock-based compensation												8,822						8,822
Warrant exercises, value						$ 38						19,390						$ 19,428
Warrant exercises, shares						37,941												27,300
Stock issued for incentive compensation and tendered for income tax												828						$ 828
Stock issued for incentive compensation and tendered for income tax , shares						323	157
Stock option exercises, value						$ 3						1,835						$ 1,838
Stock option exercises, shares						2,591												2,600
Stock issued in legal settlement, value						$ 4						(4)
Stock issued in legal settlement, shares						4,000
Conversion of Series B preferred stock to common stock, shares	(13)					131
Net loss													(154,674)					$ (154,674)
Ending balance at May. 31, 2021						$ 626						$ 489,650	$ (511,294)					$ (21,018)
Ending balance, shares at May. 31, 2021	96					626,123	443